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Abstract
GIPC1 is a cytoplasmic scaffold protein that interacts with numerous receptor signaling complexes, and emerging evidence
suggests that it plays a role in tumorigenesis. GIPC1 is highly expressed in a number of human malignancies, including
breast, ovarian, gastric, and pancreatic cancers. Suppression of GIPC1 in human pancreatic cancer cells inhibits in vivo tumor
growth in immunodeficient mice. To better understand GIPC1 function, we suppressed its expression in human breast and
colorectal cancer cell lines and human mammary epithelial cells (HMECs) and assayed both gene expression and cellular
phenotype. Suppression of GIPC1 promotes apoptosis in MCF-7, MDA-MD231, SKBR-3, SW480, and SW620 cells and impairs
anchorage-independent colony formation of HMECs. These observations indicate GIPC1 plays an essential role in oncogenic
transformation, and its expression is necessary for the survival of human breast and colorectal cancer cells. Additionally, a
GIPC1 knock-down gene signature was used to interrogate publically available breast and ovarian cancer microarray
datasets. This GIPC1 signature statistically correlates with a number of breast and ovarian cancer phenotypes and clinical
outcomes, including patient survival. Taken together, these data indicate that GIPC1 inhibition may represent a new target
for therapeutic development for the treatment of human cancers.
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Introduction
GIPC1, GIPC2 and GIPC3 comprise the human GIPC gene
family, which is characterized by a single, conserved PDZ domain
and GIPC homology (GH1 and GH2) domains [1]. GIPC1 is a
scaffold protein involved in cell surface receptor expression,
intracellular trafficking, and signal transduction. We previously
showed GIPC1 plays a central role in physiologic growth factor
signaling, endothelial cell regulation, and arterial branching
morphogenesis in both mice and zebrafish [2,3]. Moreover,
GIPC1 interacts with and stabilizes important receptor signaling
complexes, including receptor tyrosine kinases TrkA and TrkB
[4,5], VEGF co-receptor neuropilin-1 [6], FGF co-receptor
syndecan-4 [7,8], Frizzled-3 receptor [9], IGF-1 receptor [10],
the TGF-beta type III receptor [11], and endoglin [12]. These
receptor complex interactions reflect the role GIPC1 plays as an
adaptor protein, which links multiple growth factor-supported
recognition processes to intracellular signaling pathways, culmi-
nating in cell cycle regulation among other functions.
In cancer, GIPC1 was identified as an immunogenic antigen
over-expressed in both breast and ovarian tumors [13,14]. GIPC1
and GIPC2 mRNAs are expressed in OKAJIMA, TMK1,
MKN45 and KATO-III human gastric cancer cells, and in
various primary gastric tumors [15,16]. GIPC1 is highly expressed
in human pancreatic adenocarcinoma and plays a central role the
stability of IGF-1R in pancreatic adenocarcinoma cell lines
[17,18]. Most recently, GIPC1 suppression in human pancreatic
cancer cells was shown to inhibit in vivo pancreatic tumor growth in
immunodeficient mice [19]. However, the mechanism by which
GIPC1 promotes cancer growth is not well established.
To investigate the role that GIPC1 plays in cancer, we used
RNAi to suppress GIPC1 expression in both breast and
colorectal cancer cells and human mammary epithelial cells
(HMECs). We started our study by examining alterations in
global gene expression patterns after GIPC1 suppression. Our
analysis indicates that GIPC1 is required for breast and
colorectal cancer cell survival and plays an essential role in
oncogenic transformation.
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GIPC1 silencing and gene expression patterning in
MDA-MB231 human breast cancer cells
GIPC1 gene expression was knocked down in MDA-MB231
cells by transduction of short hairpin RNAs (GIPC1 KD), together
with empty-vector and non-transduced controls. Following
puromycin selection, seven independent biological replicates of
each transduction were grown in culture, RNA was extracted, and
GIPC1 knock-down was assayed using qPCR. qPCR found 85%
knock-down in GIPC1 KD cells relative to non-transduced and
empty-vector controls. RNAs from the independent pools were
hybridized to Affymetrix Human Genome U133 Plus 2.0
GeneChips
TM, data were normalized using Robust Multi-Array
Analysis [20] implemented in the Bioconductor affy package, and
exploratory analysis performed with hierarchical clustering using
the Bioconductor package, made4 [21]. A strong biological effect of
GIPC1 silencing was observed (Figure S1). Significance Analysis of
Microarrays (SAM; q-value =0%) [22] was used to identify 3081
probesets (,2271 genes) with altered expression in the GIPC1 KD
cells compared to the vector control cells.
This GIPC1 KD gene list was compared to those presented by
Bild et al. [23],who analyzed over-expression of five oncogenes
(activated H-Ras, human E2F3, activated b-catenin, human c-
Myc, and human c-Src) in primary HMECs, using OrderedList [24].
We found a statistically significant overlap of abnormally
expressed genes in the GIPC1 KD and the activated H-Ras
over-expression gene lists (P%0.05, Figure S2).
The 3081 GIPC1 KD probesets representing 2271 genes were
used in a functional enrichment analysis using Expression Analysis
Systematic Explorer (EASE) [25] and nested EASE, which applies
the EASE representational analysis iteratively to identify GO
daughter terms that drive the significance of higher-level terms
(Chittenden et al., submitted). EASE uses Fisher’s Exact Test to
identify functional classes in gene sets that are over-represented
relative to the background distribution of genes assayed. Eight of
67 over-represented gene ontology (GO) terms found by EASE are
shown in Table 1, among which are terms associated with cell
proliferation, cell cycle, cell cycle arrest, apoptosis, cell migration,
and ubiquitin-mediated protein degradation.
Nested EASE (nEASE) is an extension of EASE that uses a
second, sub-level, iterative Fisher’s Exact Test to find GO
subclasses that drive EASE term selection. The results, shown in
Table 2, include 17 statistically enriched functional subclasses of
cellular processes found by EASE. nEASE found that the EASE-
significant GO biological process classes, cell proliferation, protein
modification, mitosis, cell growth and/or maintenance, cytoskeleton organiza-
tion and biogenesis, and physiological process are collectively driven by
the biological processes cell adhesion and integrin-mediated signaling.
Similarly, EASE-significant term cytoplasm organization and biogenesis
was found by nEASE to be driven in part by cytokinesis after mitosis.
nEASE found apoptosis significant due to GO terms associated with
regulation of actin filament and the JAK-STAT signaling cascade. Altered
expression was found in genes involved in both cell migration and
metabolism; modifications in ubiquitin-protein ligase activity are due to
alterations in protein binding. nEASE also indicates that GIPC1
KD alters expression of genes in the EGF, TGFb, and WNT
receptor signaling pathways.
Collectively, these data suggest that GIPC1 is involved in cell
proliferation, apoptosis, cell motility and adhesion, and ubiquitin-
mediated protein degradation. These data suggest that GIPC1
plays a broad role beyond its early association with vascular
regulation and that it may, in cancer, be involved in the processes
associated with cell- cycle control.
GIPC1 silencing inhibits MDA-MB231 proliferation and
induces apoptosis
Because GIPC1 KD affects processes linked to cell growth, we
assessed the effects of GIPC1 depletion on MDA-MB231 cell
proliferation. We determined cell viability after GIPC1 depletion
by both resazurin and MTS tetrazolium reduction assays in
experimental and control cells. In both instances, GIPC1 silencing
Table 1. EASE analysis of GIPC1 KD in MDA-MB231 human breast cancer cells.
Accession
Type
Accession
Number Accession Term
List
Hits
List
Size
Pop.
Hits
Pop.
Size
Fisher’s
Exact
Corrected P
Value
GO Biological
Process
0016192 Cell Proliferation 277 1573 1534 12439 4.6610
28 2.0610
23
GO Biological
Process
0007049 Cell Cycle 178 1573 936 12439 2.1610
29 1.5610
26
GO Biological
Process
0000082 G1/S Transition of Mitotic Cycle Cell 25 1573 82 12439 1.6610
25 2.1610
23
GO Biological
Process
0000086 G2/M Transition of Mitotic Cycle Cell 19 1573 62 12439 1.5610
24 1.4610
22
GO Biological
Process
0007050 Cell Cycle Arrest 24 1573 98 12439 9.4610
24 5.0610
22
GO Biological
Process
0006915 Apoptosis 150 1573 818 12439 9.0610
27 2.0610
24
GO Biological
Process
0030334 Regulation of Cell Migration 23 1573 81 12439 1.2610
24 1.2610
22
GO Biological
Process
0006511 Ubiquitin-Dependent Protein Catabolism 89 1573 489 12439 2.1610
24 1.7610
22
Table 1 presents eight over-represented EASE functional classes. The list of functional annotation classes analyzed include: GO terms for biological process, molecular
function, and cellular component. Pop Size is the number of genes assigned to a particular annotation class. Pop Hits is the number of genes assigned to a particular
annotation term. List Size indicates the number of differentially genes with assignments in each annotation class. List Hits is the number of differentially genes associated
with each particular GO term. The Fisher’s Exact column lists the p-value from Fisher’s Exact test. The corrected p-value column indicates the p-value after correction for
multiple testing by the Benjamini-Hochberg method.
doi:10.1371/journal.pone.0015581.t001
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seeding (Figure 1A and 1D). Since GIPC1 interacts with
neuropilin-1[6], cells were treated with VEGFA (10 ng/ml) to
determine whether the loss of cell viability caused by GIPC1
suppression could be overcome by a relevant mitogen. VEGFA
treatment is not sufficient to prevent an approximate 40% and
60% reduction in cell viability in GIPC1 KD cells at 48 and
72 hours, respectively (Figure 1D).
GIPC1 KD also influences apoptosis. To determine the effects
GIPC1 silencing on caspase 3/7 activity, the fluorometric
resazurin reduction assay shown in Figure 1A was multiplexed
with an Apo-ONE homogeneous caspase-3/7 assay. When
caspase 3/7 activities are normalized to cell viability values, we
detected a significant increase in caspase 3/7 activity in GIPC1
KD cells when compared to control cell lines at 72 hours
(Figure 1B). We found similar losses of cell viability and increased
caspase 3/7 activities after GIPC1 silencing in the MCF-7 and
SKBR-3 human breast cancer and SW480 and SW620 human
colorectal cancer cell lines (data not shown).
To determine whether the increase in caspase 3/7 activity
found in MDA-MB231 cells is associated with DNA fragmenta-
tion, we performed a DeadEnd colorimetric TUNEL assay
(Figure 1C). GIPC1 targeting induces DNA fragmentation;
assessed as a ratio relative to control cells, the relative ratio of
apoptotic cells (GIPC1 KD/non-target) is 11.24 (P,0.05).
Moreover, the increase in both caspase 3/7 activity and DNA
fragmentation in GIPC1-silenced cells are associated with an
increased expression of cleaved PARP1 (Figure 1D). These data
are consistent with the microarray findings (Tables 1 and 2), which
indicate GIPC1 silencing inhibits cell proliferation and promotes
apoptosis.
GIPC1 silencing induces MDA-MB231 G2 cell-cycle arrest
Microarray results implicated cell cycle effects of GIPC1 KD.
We performed single-channel FACS analysis of GIPC1 KD cells
and the associated controls to explore the cell cycle in control and
GIPC1 KD cells. GIPC1 suppression promotes subtle G1 and
profound G2 arrest at day 14 post-puromycin selection of the
GIPC1 shRNA transfectants (Figure 2A). These data indicate
accumulation of cells in both G1 (43.70%61.86% cells vs.
38.58%60.21%) and G2 (46.33%61.29% vs. 27.70%60.67%)
phases of the cell cycle in GIPC1 KD compared to non-target
control cells. GIPC1 KD cells continue to traverse S phase against
the prominent G2 arrest (9.98%60.57% vs. 33.73%60.53%).
GIPC1 knockdown also results in a significant accumulation of
cells in an 8N DNA peak (9.74%60.67% vs. 0%) and in cellular
debris (sub-G1; 5.52%60.54% vs. 1.57%60.17%). Along with the
microarray findings presented in Tables 1 and 2, and compared to
appropriate controls, these data suggest GIPC1 suppression
promotes cell division arrest and apoptosis.
Table 2. nEASE analysis of GIPC1 KD in MDA-MB231 human breast cancer cells.
nEASE Term
List
Hits
List
Size
Pop.
Hits
Pop.
Size
Fisher’s
Exact
Gene
Enrich
nEASE
pvalue
Diff
nEASE
Gene
Enrich
% Gene
Enrich EASE Term
Cell Adhesion 27 277 104 1534 2.4610
22 8.22 1.46 12.46 7.90 Cell Proliferation
Focal Adhesion Formation 4 655 10 4596 4.2610
22 2.57 0.11 0.09 25.75 Cell Growth and/or
Maintenance
Cell Adhesion 3 49 4 227 3.2610
22 2.14 1.34 6.38 53.41 Mitosis
Cell Adhesion 14 83 37 457 2.5610
23 7.28 2.44 11.52 19.67 Cytoskeleton organization
and Biogenesis
Actin filament Based Movement 2 277 2 1534 3.3610
22 1.64 0.87 0.17 81.94 Cell Proliferation
Negative Regulation of RHO Protein
Signal Transduction
2 277 2 1534 3.3610
22 1.64 0.87 0.17 81.94 Cell Proliferation
Cytokinesis after Mitosis 3 122 3 735 4.5610
23 2.50 0.21 0.01 83.40 Cytoplasm Organization
and Biogenesis
Establishment of Apical/Basal
Cell Polarity
2 213 2 1307 2.7610
22 1.67 0.67 0.31 83.70 Protein Modification
Integrin-Mediated Signaling Pathway 10 1451 39 10985 2.7610
22 4.85 0.56 1.05 12.43 Physiological Process
Regulation of Actin Filament Length 4 150 4 818 1.1610
23 3.26 1.84 0.60 81.66 Apoptosis
Positive Regulation of JAK-STAT
Cascade
2 150 2 818 3.3610
22 1.64 0.38 0.14 81.66 Apoptosis
Positive Regulation of Cell Migration 9 1054 22 7530 1.8610
23 5.92 0.83 0.84 26.91 Metabolism
Ubiquitin-Protein Ligase Activity 20 1481 95 11233 2.2610
22 7.50 0.42 0.99 7.86 Binding
EGF Receptor Signaling Pathway 6 118 13 705 1.2610
22 3.82 0.74 0.25 29.42 Regulation of Cellular
Process
TGFBeta Receptor Signaling Pathway 24 1451 96 10985 1.3610
23 11.32 0.32 0.35 11.80 Physiological Process
Transforming Growth Factor Beta
Receptor Activity
6 123 13 727 1.3610
22 3.80 0.72 0.22 29.24 Regulation of Biological
Process
WNT Receptor Signaling Pathway 17 1451 80 10985 3.0610
22 6.43 0.77 2.50 8.04 Physiological Process
Table 2 presents 17 over-represented nEASE functional classes nested within enriched EASE GO terms of the upper-level EASE analysis. Gene Erich indicates the number
of differentially expressed genes above what is expected for the nEASE List Hits category based on the EASE GO term enrichment. Pvalue log diff indicates the Fisher’s
Exact Test p-value log difference between the same nEASE and EASE GO terms. nEASE Gene Enrich presents the enriched gene value based on the same EASE Gene
Enrich value. % Gene Enrich column indicates percent gene enrichment for each nEASE GO Term based on the Gene Enrich value.
doi:10.1371/journal.pone.0015581.t002
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GIPC1 suppression, we used Western blotting to evaluate protein
expression of known cell-cycle check-point regulators found
differentially expressed in the microarray analysis. GIPC1 silencing
induces a loss of Cdc25b and an increase in GADD45a/c protein
expression (Figure 2B). CDC25b is required for CDK1 activation
Figure 1. The effects of GIPC1 silencing on cell proliferation and apoptosis in MDA-MB231 human breast cancer cells. A. Assessment
of cell viability (blue) and caspase 3/7 activity (pink) at 0, 24, 48, and 72 hours. Solid lines with blue boxes (non-transduced) and blue diamonds (non-
target) and dashed line with blue triangles (GIPC1 KD) indicate cell viability. Pink denotes caspase 3/7 activity. B. Normalized caspase 3/7 activity. Total
caspase 3/7 activity was normalized to cell viability and assessed at 0, 24, 48, and 72 hours. Normalization indicates a 2.1 fold increase in caspase 3/7
activity in GIPC1 KD cells compared to non-target cells at 72 hours. C. Tunnel assay. DNA fragmentation was assessed as % positive control. GIPC1 KD
correlates with an 11.24 fold increase in apoptosis (GIPC1/Non-target; P,0.05). D. Evaluation of cell proliferation after VEGF (10 ng/ml) induction.
Proliferation was evaluated at 0, 24, 48, and 72 hours. Days 1, 2, and 3 were normalized to day 0. Solid lines with blue boxes (non-transduced) and
blue diamonds (non-target) and dashed line with blue triangles (GIPC1 KD) indicate cell proliferation in starvation media. Pink denotes VEGF
induction. D. Evaluation of cleaved PARP1. PARP1, cleaved PARP1, GIPC1, and GAPDH expression was assessed by western blot in MDA-MB231
human breast cancer cells. Data are presented as means 6 SEM. Asterisks indicate statistical significance (P#0.05) between non-target and GIPC1 KD
conditions.
doi:10.1371/journal.pone.0015581.g001
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family members are increased following growth arrest and DNA
damage. These findings support both the microarray (Tables 1 and
2) and FACS (Figure 2A) results indicating that GIPC1 suppression
predominantly promotes G2 arrest.
GIPC1 suppression alters cell adhesion and motility
Microarray findings suggest GIPC1 is involved in adhesion and
motility (Tables 1 and 2). We assessed the effects of GIPC1
silencing on cell motility and adhesion in MDA-MB231
experimental and control cells. GIPC1 silencing significantly
enhanced MDA-MB231 cell adhesion at both 30 and 60 minutes
after plating (Figure S3A). We used a scratch (wound) assay to
assess the effects of GIPC1 KD on cell motility. GIPC1
suppression significantly decreased MDA-MB231 cell migration,
either with or without eight hours of growth factor induction
(Figure S3B). Microarray findings indicate GIPC1 suppression is
associated with an enrichment of abnormally expressed genes
within the integrin-mediated, RHO protein, JAK-STAT, EGF,
Ras, TGFb and WNT pathways (Table 2 and Figure S2). These
pathways, first found in our bioinformatics analysis, regulate both
cell adhesion and migration and are candidates for further
investigation. Experimentally, GIPC1 depletion results in en-
hanced cell adhesion and reduced cell motility. GIPC1 depletion
results in loss of EGF, FGF2, PDGF-BB, TGFb1, and VEGFA
induced cell motility (Figure S3B). These data suggest that GIPC1
plays a role in a number of important signal transduction pathways
that impinge on both cell adhesion and motility.
GIPC1 is required for anchorage-independent colony
formation of the tHMEC-LT-st cell line
To assess whether GIPC1 is required for oncogenic transfor-
mation, we suppressed its expression in hTERT-immortalized
HMECs transformed with SV40 Large T (LT) and Small T (st)
antigens (tHMEC-LT-st) [26]. tHMEC-LT-st cells are capable of
anchorage-independent growth; however, GIPC1 depletion sig-
nificantly reduced the efficiency of anchorage-independent colony
formation of the tHMEC-LT-st cell line when compared to
control cells. As an additional control, a second GIPC1 shRNA
construct was used in this set of experiments (Figure 3A). These
data indicate that GIPC1 is required for anchorage-independent
colony formation, a measure of oncogenic transformation of
HMEC cells.
Clinical relevance of genes regulated by GIPC1
knock-down
To further assess the assumption that GIPC1 plays a significant
role in the development and progression of human cancers, 411
probesets with a fold-change $2 in SAM analysis of GIPC1
depleted MDA-MB231 cells compared to control cells (GIPC1
signature; Table S1) were used to interrogate two publicly
available and clinically annotated breast and ovarian cancer
datasets with the Bioconductor package, globaltest [27]. A large
merged breast cancer DNA microarray dataset with 689
pretreatment samples [28,29,30] and an ovarian cancer dataset
with 274 treated patients [31] were used for the analysis. In the
Global Test multivariate analysis of the 689 breast cancer patients,
Figure 2. Single channel FACS analysis of GIPC1 KD MDA-MB231 human breast cancer cells. A. Single channel FACS analysis of non-
transduced, non-target, and GIPC1 KD cells 14 days post-transduction. Grey is % cells in G1. Yellow indicates % cells in S phase. Orange equals % cells
in G2. Blue is % cells at 8N. D indicates % debris. B. Western blot analysis of Cdc25b, GIPC1, and GADD 45 a/c expression in non-transduced, non-
target, and GIPC1 KD cells. Data are presented as means 6 SEM. Asterisks indicate statistical significance (P#0.05) between non-target and GIPC1 KD
conditions.
doi:10.1371/journal.pone.0015581.g002
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lymph node status (P,0.0001), and ER status (P,0.05). The
GIPC1 signature is also strongly associated patient survival within
the ERBB2+/ER+ (n=42, P,0.001), luminal B (n=146,
P,0.05) and basal (n=92, P,0.01) molecular breast cancer
subtypes (Table 3). Analysis of the ovarian cancer dataset indicates
that the GIPC1 signature is significantly associated with all clinical
variables assessed; including patient survival and tumor stage,
grade, and type (Table 3). These data support recent reports
suggesting that GIPC1 plays a role in human breast and ovarian
cancer etiology and progression [13,14].
Discussion
Little is known about the role of GIPC1 in tumor growth and
progression. Evidence indicates it is highly expressed in a number
of human malignancies, including breast, ovarian, gastric, and
pancreatic cancers [13,14]. Moreover, a recent report shows
GIPC1 is required for in vivo pancreatic tumor growth in
immunodeficient mice [19]. In this study, we used both
computational and experimental approaches to examine GIPC1
in human breast and colorectal cancer cells, and in patients with
breast and ovarian cancer. We found that GIPC1 is required for
breast and colorectal cancer cell survival, and it plays an essential
role in oncogenic transformation of human mammary epithelial
cells.
Our data also show GIPC1 plays an important role in cell cycle
regulation. EASE analysis of GIPC1 knockdown in MDA-MB231
cells shows enrichment of differentially expressed genes with
annotated functions in G1/S and G2/M transitions, cell cycle
arrest, cell proliferation, and apoptosis. nEASE seeks biological
explanations for these main effects and implicates potential
abnormalities in cell adhesion, integrin-mediated signaling, and
regulation of the actin cytoskeleton. Additionally, nEASE found an
enrichment of genes involved in cytokinesis. This finding is in
agreement with a recent report indicating that activation of
syndecan-4 (SDC4), a transmembrane heparan sulfate proteogly-
can that interacts with GIPC1 and the FGFR1 receptor to regulate
FGF2 signaling, is required for cytokinesis of MCF-7 human
breast cancer cells [32]. Keller-Pinter et al. showed that serine179-
phosphorylation and ectodomain shedding of SDC4 is maximal at
G2/M. Expression of engineered mutants mimicking serine 179-
phosphorylation (Ser179Glu) or phosphorylation-resistant SDC4
caused incomplete abscission and giant, multinucleated cells [32].
In addition, SDC4 regulates actin polymerization, focal adhesion
formation, and cell motility through PI3K signaling.
nEASE analysis also suggests that GIPC1 is involved in six
major signal transduction networks in breast cancer: integrin-
mediated, RHO protein, JAK-STAT, EGF, TGFb and WNT.
These findings support previous reports indicating that GIPC1
interacts with the Frizzled-3 receptor [9], the TGF-beta type III
receptor [11], and endoglin [12]. Despite the fact that our analysis
did not suggest an enrichment of genes within the PI3K signal
transduction network, we find that GIPC1 suppression decreases
expression of a number of key genes involved in the pathway,
including SDC2, PIK3CB, PIK3D, PDK1, AKT3, CDC42BPA,
CDC42EP3, RACGAP1, and RAC1. Conversely, GIPC1 silencing
promotes significant elevations in gene expression for PTEN,
p27
Kip1, RHOBTB1, RHOB, and PAK2. While aberrant activation
of PI3K signaling is involved in the induction of oncogenic
transformation, these genes work in concert to integrate
mechanisms that control a number of cellular processes, including
cytoskeleton regulation, cell motility and adhesion, cell prolifera-
tion, and apoptosis [26,33].
Experimental validation of the gene expression profiling results
indicates that GIPC1 silencing promotes G2 cell-cycle arrest,
apoptosis, and alternations in cell adhesion and motility in MDA-
MB231 human breast cancer cells. GIPC1 depletion correlates
with increased caspase 3/7 activity, DNA fragmentation, upregu-
lation of GADD45 family members, and loss of Cdc25b
expression. Moreover, GIPC1 silencing correlates with marked
reductions in cell viability and evaluations in caspase 3/7 activities
in MCF-7 and SKBR-3 human breast cancer and SW480 and
SW620 human colorectal cancer cells.
B yu s i n gR N A it od e p l e t eG I P C 1m R N Ai nM D A - M B - 2 3 1
cells we were able to identify a wide range of genes whose
expression was altered. We compared this GIPC1 signature to
Table 3. Clinical relevance of the set of top 411 differentially
expressed GIPC1 KD probesets (absolute fold change . 2) to
human breast and ovarian cancers.
Merged Breast Cancer Dataset (N=689)
Clinical Variable p-value
Recurrence-free survival 0.091
ER status 0.034
Tumor Size 0.060
LN status 8.7610
25
Tumor Grade 0.0034
Age 0.065
Basal subtype 5.6610
222
ERBB2+/ER- subtype 3.2610
26
ERBB2+/ER+ subtype 0.016
Luminal A subtype 4.4610
234
Luminal B subtype 1.9610
211
Survival within basal subtype (n=92) 0.0074
Survival within ERBB2+/ER- subtype (n=60) 0.071
Survival within ERBB2+/ER+ subtype (n=42) 4.3610
24
Survival within luminal A subtype (n=321) 0.13
Survival within luminal B subtype (n=146) 0.015
Ovarian Cancer Dataset (N=274)
Clinical Variable p-value
Overall survival 0.012
Tumor Stage 0.012
Tumor Grade 9.6610
25
Tumor Type (malignant vs. low malignant) potential) 5.5610
213
p-values correspond to the significance of the gene set as a predictor for the
specified clinical variable, while controlling for all other variables assessed.
doi:10.1371/journal.pone.0015581.t003
Figure 3. The effects of GIPC1 silencing on anchorage-independent colony formation of tHMEC-LT-st cells. A. Soft agar colony
formation in nontransduced, non-target, and GIPC1 KD tHMEC-LT-st cells cells. B. Western blotting indicating the effectivness of GIPC1 silencing with
two independent GIPC1 shRNA contructs: NM_005716.2-1083s1c1 and NM_005716.2-499s1c1. Data are presented as means 6 SEM. Asterisks indicate
statistical significance (P#0.05) between non-target and GIPC1 KD conditions.
doi:10.1371/journal.pone.0015581.g003
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datasets for which well-annotated phenotype and outcome data
were available. We found strong correlation between the
GIPC1 signature and a number of important patient clinical
variables.
In breast cancer, we used Global Test methodology and found
recurrence-free survival was significantly associated with the
GIPC1 signature only within specific molecular subtypes of the
disease: patients with luminal B ER+ tumors (high-grade ER+;
P=0.015), ERBB2+/ER+ disease (P=4.3610
24), and perhaps
basal-like or triple-negative cancers (P=0.0074). Within luminal
AE R + (low-grade ER+) cases and patients with ERBB2+/ER-
cancers, the GIPC1 signature was not predictive of recurrence-
free survival. Therefore, the GIPC1 signature may be capable of
distinguishing patient outcome within groups of high-grade
breast cancers, particularly those that are ER+, and not simply
distinguishing tumor grade (high vs. low) or ER status (positive
versus negative). In the ovarian cancer dataset, the GIPC1
signature is statistically correlated with all clinical variables
assessed: overall survival and tumor grade, type, and stage. One
common feature of the correlations we found between the
GIPC1 signature and clinical parameters in breast and ovarian
cancer was an association with high-grade tumors that are
characterized by excessive DNA damage and poor patient
prognosis.
The available expression data indicate that GIPC1 is highly
expressed in every human cancer and our results suggest GIPC1 is
a necessary component for human cancer growth promoted by
upstream growth factors and their receptors. Because GIPC1
signal transduction is activated by a wide range of cell-surface
receptors and because it is also known to be essential for branching
morphogenesis of arterial blood vessels, targeting GIPC1 mediated
pathways is a logical therapeutic strategy for the treatment of
human cancers. In particular, our data suggests targeting GIPC1
may be particularly important for estrogen receptor-positive high-
grade breast cancers.
Materials and Methods
Cell culture
The MCF-7, MDA-MB231, and SKBR-3 human breast cancer
cell lines and the SW480 and SW620 human colorectal cancer cell
lines were purchased from ATCC. Human mammary epithelial
cells (HMECs) were purchased from Invitrogen (#A-10565).
Primary HMEC experiments were performed # passage 10.
hTERT-immortalized HMECs expressing SV40 LT and st were
cultured as previously described [26]. All cell lines were cultured in
100620 mm tissue culture dishes (Becton Dickinson #353803).
MCF-7 cells were cultured at 37uC and 5% CO2 in EMEM
(GIBCO #11095-080) supplemented with 10% heat-inactivated
Fetal Bovine Serum (ATCC #30-2020) and 1% Antibiotic-
Antimyotic (Invitrogen #15240-062). MDA-MB231 cells were
cultured at 37uC and 0% CO2 in Leibovitz’s L-15 media (GIBCO
#11415-064) supplemented with 10% FBS and 1% Antibiotic-
Antimyotic. SKBR-3 cells were cultured at 37C and 5% CO2 in
McCoy’s 5A media (GIBCO #12330-031) supplemented with
10% FBS and 1% Antibiotic-Antimyotic. SW480 and SW620 cells
were cultured at 37uC and 0% CO2 in Leibovitz’s L-15 media
supplemented with 10% FBS and 1% Antibiotic-Antimyotic.
Primary HMECs were cultured at 37uC and 5% CO2 in Medium
171PRF (phenol red-free) (GIBCO #M-171PRF-500) supple-
mented with mammary epithelial growth supplement (MEGS)
(GIBCO #S-015-5) and 1% Antibiotic-Antimyotic. All cell lines
were maintained at 60-70% confluency.
shRNA lentiviral vector production and transduction
GIPC1(NM_005716.2-1083s1c1 and NM_005716.2-499s1c1)
and empty vector shRNA plasmids as well as the Delta 8.9 and
VsVg plasmids were obtained from The RNAi Facility at the
Dana-Farber Cancer Institute. A scrambled, non-target shRNA
plasmid was purchase from Sigma (#SHC002). cDNA versions of
SV40 LT + st (LTg) were cloned into pWZL-blast as previously
described[26]. All plasmids were grown in LB Broth +100 mg/ml
Ampicillin (Teknova #L8105). Plasmids were purified using the
Qiagen HiSpeed Plasmid Maxi Kit according to the manufactur-
er’s instructions (Qiagen #12663), and yields were assessed using
a NanoDrop spectrophotometer (Thermo Scientific #SID-
10135606). HEK 293T/17 cells (ATCC # CRL-11268) were
expanded to a density of 5610
6/100 mm cell culture dish (BD
Primaria #353803) in Dulbecco’s Modified Eagle’s Medium
(ATCC #30-2002) +10% heat-inactivated Fetal Bovine Serum
(ATCC #30-2020) and incubated at 37uC, 5% CO2 for 24 hours.
Each plate was then transfected with FuGENE 6 Transfection
Reagent (Roche #11814443001), VsVG purified plasmid, Delta
8.9 purified plasmid, and either 6 mg of shRNA purified plasmid
or 4 mg of purified LTgWB plasmid in OptiMem media (Invitrogen
#11058-021). Media was changed one day after transfection with
DMEM +10% FBS media containing 1% Antibiotic-Antimyotic
(Invitrogen #15240-062). Media containing the packaged virus
was collected on day 2 after transfection, fresh media was added,
and the viral harvest was collected again on day 3 after
transfection. The packaged lentivirus was filtered with 0.45 mm
filters (Corning #431220) and concentrated for 90 minutes at
16,600 g using an ultracentrifuge (Beckman #L8-70M). After
resuspension, the lentivirus was titered using the QuickTiter
Lentivirus Quantitation Kit (Cell Biolabs #VPK-108-HIV) per
the manufacturer’s instructions. For lentiviral shRNA vector
transduction, growth media containing polybrene and a volume
of lentivirus that equated to an MOI of 50 was added to cells and
incubated overnight in cell line specific culture conditions. Next
day, virus media was replaced with cell line specific growth media.
At 72 hours, growth media was supplemented with either 10 mg/
mL of puromycin and/or 2.5 mg/ml blasticidin. Experiments were
performed 14 days after selection.
RNA isolation, microarray hybridization and processing,
and quantitative PCR
Total RNA was isolated from cell lines using the RNeasy Mini
Kit (Qiagen #74106) accordingto the manufacturer’s specifications
with QIAshredder columns (Qiagen #79656) for cell pellet
homogenization. Total RNA was quantified using a NanoDrop
spectrophotometer (Thermo Scientific #SID-10135606). Twenty
one Affymetrix GeneChip Human Genome U133 Plus 2.0 Arrays
were used for this study. Seven arrays per group were used for the
following MDA-MB231 cell lines: non-transduced, empty vector,
and GIPC1 KD. Microarray hybridization and processing was
performed using standard protocols at the Microarray Core Facility
at the Dana-Farber Cancer Institute. Sample processing was
performed with an Affymetrix GeneChip Fluidics Station FS450
andarrayswerescanned with a GCS300 arrayscanner accordingto
manufacturer’s recommendations. Two-step Quantitative Real-
Time PCR was performed with an Applied Biosystems 7900HT
(Applied Biosystems #4329001) system. TaqMan GIPC1(Applied
Biosystems #Hs00991802_m1) and 18S Endogenous Control
(Applied Biosystems #4304437) assays were run at 8 replicates
per sample using the Relative Quantification (Delta Ct), FAM no
quench settings. Delta Cts were calculated by subtracting the
average Ct of the endogenous controls from the average Ct of the
amplification target. The delta-delta Ct was calculated by
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the average delta Ct of the target vector samples. Fold change was
calculated as 2 to the power of delta-delta Ct.
Microarray data normalization and analysis
Raw data (.cel files) were imported into R and data were
normalized with RMA [20] using the Bioconductor package, affy.
Initial exploratory data analysis was performed with hierarchical
clustering analysis (average-linkage and metric 1 - Pearson
correlation coefficient distance) using the Bioconductor package,
made4[21]. Two class unpaired Significance Analysis of Micro-
arrays (SAM;[22] with a 0% false discovery rate (q-value) was used
to determine differential gene expression between empty vector
control and GIPC1 KD MDA-MB231 cells.
The nested Expression Analysis Systematic Explorer (nEASE)
algorithm (Chittenden et al., submitted) which is implemented
along with SAM in the TM4 Multiple Experiment Viewer
(MeV)[34], was then used to determine iterative sub-level,
biological classifications for biological process, molecular function,
and cellular component gene ontology (GO) terms [35]. To assess
the likelihood that GO terms arise at a greater frequency than
what would be expected by chance, nEASE generates a P-value
from gene tallies associated with statistically enriched EASE [25]
GO terms that are corrected for multiple hypothesis testing by the
Benjamini-Hochberg method [36]. The gene counts associated
with each enriched EASE GO term are used as background
distributions for the purposes of deriving iterative sub-level nEASE
hypergeometric distributions via the Fisher’s Exact Test for each
individual EASE GO term.
Analysis of clinical breast and ovarian cancer public
datasets
The clinical relevance of the GIPC1 KD signature (n=411
probesets) was evaluated in publicly available breast and ovarian
cancer gene expression data which were downloaded from the
Gene Expression Omnibus database at NCBI. After excluding patients
with missing clinical data, the breast cancer dataset contained 689
gene expression profiles that were obtained by merging the
datasets GSE6532 [30], GSE4922 [29], and GSE7390 [28]. The
ovarian cancer dataset contained 274 gene expression profiles
from GSE9891 [31].
Association between gene expression of the GIPC1 KD
signature and each clinical variable in the breast and ovarian
cancer datasets were evaluated using globaltest [27]. Resulting P-
values were adjusted for multiple testing using the Hommel
approach within the ‘‘p.adjust’’ function of the limma package of
Bioconductor. Ovarian and breast cancer data were treated as two
independent groups of tests in multiple testing corrections. In
order to relate the gene signature to specific clinical variables and
avoid confounding with other correlated clinical variables, tests of
a variable of interest were done while controlling all other clinical
variables in the model.
Breast clinical variables included molecular subtype, lymph
node status, estrogen receptor status, size, age, grade, and
recurrence-free survival. Grade was treated as an ordered
categorical variable. Ovarian clinical variables were size, grade,
type (malignant versus. low malignant potential) and overall
survival.
Analysis of merged MDA-MB231 GIPC1 KD and HMEC
oncogene signature dataset
An HMEC oncogene signature dataset, GSE3151 [23]was
merged with the MDA-MB231 GIPC1 KD dataset. The merged
dataset was normalized with RMA [20] using the Bioconductor
package, affy. A meta-analysis was performed with the Biocon-
ductor R package, OrderedList with default parameters [24], to
determine the degree of overlap in differential gene expression
between the GIPC1 KD MDA-MB231 cell line and each of the
five HMEC oncogene expression cell lines (H-Ras, E2F3, b-
catenin, c-Myc, c-Src).
Western blotting
Whole cell lysates were prepared and then separated by SDS-
PAGE in the following manner: cells were washed in cold PBS and
lysed in cold RIPA buffer (Boston BioProducts #BP-115)
containing both protease (Roche #11-873-580-001) and phos-
phatase (Sigma #P2850-5mL and #P5726-5mL) inhibitors.
Protein concentrations were determined with a BCA protein
assay kit (Pierce #23225) according to manufacturer’s recom-
mendations. Protein samples were subjected to 10% SDS-PAGE
and then transferred onto PVDF membranes (Bio-RAD #162-
0239). Membranes were blocked for 1 hour at room temperature
in 5% non-fat milk/TBST (0.1% Tween20), and then incubated
overnight at 4uC according to manufacturer’s recommendations
with the following antibodies: cdc25B (Cell Signaling #9525),
GIPC1 (Santa Cruz Biotechnology #sc-9648), GAPDH (Santa
Cruz Biotechnology #sc-32233), GADD 45a/c (Cell Signaling
#3518), and PARP (Cell Signaling #9542). Immunoblots were
incubated with primary antibody specific, horseradish peroxidase-
conjugated secondary antibodies from Santa Cruz Biotechnology
and Cell Signaling and then developed with SuperSignal West
Pico Chemiluminescent Substrate (Pierce #34078). Densitometry
was performed with Scion Image software.
Fluorescence-activated cell sorting analysis
DNA content and cell cycle progression was evaluated in
GIPC1 KD, non-target, and non-transduced MDA-MB231 cell
lines by a standard BrdU and propidium iodide (PI) double
staining method at the Flow Cytometry Core Laboratory of the
Dana-Farber Cancer Institute. Samples were analyzed using a
FACScan flow cytometer analyzer and CellQuest software (Becton
Dickinson). The FITC Mouse Anti- BrdU Set (anti-BrdU-FITC:
51-33284X and irrelevant IgG-FITC: 51-35404X-2) was pur-
chased from BD Pharmingen.
Soft agar oncogenic transformation assay
Anchorage-independent growth assays were performed as
previously described[26]. Briefly, 5610
4 experimental and control
tHMEC-LT-st cells were seeded in 60 mm plates with a bottom
layer of 0.6% Bacto agar in DMEM and a top layer of 0.3% Bacto
agar containing MEGM. Fresh MEGM (0.5 ml) was added after
1.5 weeks and colonies were scored after 3 weeks. Only those
colonies $0.2 mm in diameter were counted. Colonies were
imaged with a VistaVision inverted microscope and a XLI-Cap
USB2.0 high resolution camera. At least two independent assays
were performed in triplicate.
Cell proliferation/viability and apoptosis assays
Anchorage-dependent growth assays were performed with a
CellTiter 96 AQueous One Solution Cell Proliferation Assay
(Promega # G3582) and a CellTiter-Blue Cell Viability (Promega
# G8082) assays. The CellTiter 96 AQueous One Solution Cell
Proliferation Assay was used to assess cell proliferation for
72 hours in non-transduced, non-target, and GIPC1 KD MDA-
MB231 human breast cancer cell lines. Cells were seeded in
triplicate at a density of 5610
3 in 100 mL of L-15 normal growth
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for 2 hours at 37uC, 0% CO2. Cells were serum starved in L-15
starvation media with 0.5% FBS for 24 hours. Media was then
replaced with 100 mL of L-15 starvation media supplement with
either VEGF (10 ng/ml) or 0.1% BSA/PBS. Immediately after
media replacement, 20 ml of Cell Titer 96 AQueous One Solution
Reagent (Promega # G358A) was added to day 0 wells and plates
were then incubated for 2 hours at 37uC, 0% CO2. Absorbance
was recorded at 492 nm using a standard ELISA 96-well plate
reader (Bio-Rad MPM III 1.133). This procedure was repeated
every 24 hours for 72 hours to assess cell proliferation.
To assess caspase 3/7 activity, CellTiter-Blue Cell Viability
(Promega # G8082) and Apo-ONEH Homogeneous Caspase-3/7
(Promega # G7792) assays were multiplexed according to
manufacturer’s recommendations. With the exception of growth
factor induction, experimental and control cells were cultured as
described above. On day 0, 20 ml/well of CellTiter-Blue Reagent
was added to each well and incubated for 2 hours in normal L-15
growth media at 37uC, 0% CO2. CellTiter-Blue fluorescence (cell
viability) was then recorded at 544ex/590em with a standard 96-
well fluorescent plate reader (BMG LabTech, FluoStar Optima).
An equal volume of 1:100 Apo-ONE Reagent (caspase substrate
Z-DEVD-R110: buffer) was then added to Day 0 wells and
incubated for 30 mins at room temperature on shaker. Apo-ONE
fluorescence (caspase 3/7 activity) was recorded at 485ex/520em.
This procedure was repeated every 24 hours for 72 hours to assess
caspase 3/7 activity. Caspase 3/7 activity was normalized to
GIPC1 KD cell viability. Apoptosis was evaluated with a DeadEnd
Colorimetric TUNEL system (Promega #G7130) according to
manufacturer’s recommendations. Briefly, non-transduced, non-
target, and GIPC1 KD MDA-MB231 cell lines were cultured in
normal L-15 growth media and MDA-MB231 culture conditions
on Poly-Prep microscope slides (Sigma #PO425). Cells were fixed
in 4% paraformaldehyde and permeabilized with 0.2% Triton X-
100. Positive controls were treated with DNase I buffer containing
10 unit/ml of DNase I (Promega #M6101). Experimental and
positive controls cells were treated with rTdT reaction mix
containing equilibration buffer, biotinylated nucleotide mix, and
rTdT enzyme. For the negative control rTdT reaction mix, rTdT
enzyme was replaced with deionized water. The rTdT reactions
were terminated with 20X SSC and endogenous peroxidase
activity was blocked with 0.3% hydrogen peroxide. Slides were
treated with Streptavidin HRP solution, 1:500 in PBS. Slides were
then developed with DAB solution for 10 mins. Slides were
mounted with Permount Mounting Media (Fisher # SP15-100)
and imaged at 10X with an Olympus BX41 light microscope and
MicroPlubisher Color CCD digital camera. DNA fragmentation
was assessed as percent positive control.
Adhesion assay
GIPC1, non-target, and non-transduced MDA-MB231 cell lines
were plated in 12-well tissue-culture plates in triplicate at 5610
4
cells/well and allowed to attach for either 30 or 60 mins. Adherent
cells were fixed with 3.7% PFA in PBS and then stained with
Coomassie blue. Wells were imaged with a VistaVision inverted
microscope and a XLI-Cap USB2.0 high resolution camera. Cell
adhesion was determined relative to total cells plated.
Wound (scratch) migration assay
The bottoms of 6-well tissue-culture plates were gridded for
accurate measurement. 2610
5 GIPC1, non-target, and non-
transduced MDA-MB231 cell lines were plated/well in triplicate.
Cells were allowed to reach confluence and then serum starved in
0.5% FBS L-15 media for 24 hours. Scratches in cell lawns were
made with a P20 pipette tip at ,1 mm on each side of each
gridline. Media was then aspirated and 0.5% FBS L-15 control
media was added to each control well. 0.5% FBS L-15 control
media was supplemented with one of the following growth factors
and added to growth factor-specific experimental wells: EGF
(50 ng/ml); FGF2 (10 ng/ml); PDGF-BB (50 ng/ml); TGFB1
(5 ng/ml); or VEGF (10 ng/ml). Wells were imaged with a
VistaVision inverted microscope and a XLI-Cap USB2.0 high
resolution camera at zero and eight hours post-wounding. Total
migration distance was determined with XLI-Cap measurement/
capture software.
Statistical analysis of cell assays
Data are presented as means 6 SEM. Results from a minimum
of three independent experiments with six replicates per condition
were performed on separate cell passages for each assay. Data
were analyzed by repeated measures ANOVA. If analysis showed
a significant difference (p#0.05) among groups, the Student-
Newman-Keuls (SNK) test for multiple comparisons of means was
performed to identify the conditions that were different from one
another. Asterisks indicate statistical significance (p#0.05) between
non-target and GIPC1 KD conditions.
Supporting Information
Figure S1 Hierarchical clustering and presentation of
RMA normalized microarray data. GI(blue): GIPC1 KD
MDA-MB231 cells; PL(green): Empty vector MDA-MB231 cells
control cells; CO(red): non-transduced MDA-MB231 control cells.
(TIF)
Figure S2 Gene list overlap. Figure S1 shows the statistically
assessed overlap of differentially expressed genes between MDA-
MB231 GIPC1 KD and HMEC H-Ras, E2F3, b-CAT, c-MYC,
and c-SRC overexpression experiments.
(TIF)
Figure S3 The effects of GIPC1 silencing on cell
adhesion and cell motility in MDA-MB231 human breast
cancer cells. A. Cell adhesion assay: 5610
4 cells were plated/
well in 12 well tissue culture plates. Cell adhesion was evaluated
relative to total cells plated at 30 and 60 minutes after seeding at
206 magnification with an inverted microscope. B. Scratch
(wound) Assay: 1610
5 cells were plated/well in 6 well tissue
culture plates. Cells were allowed to reach confluence and then
serum starved for 24 hours. A wound (scratch) was made with a
P20 pipette tip. Cells were stimulated with EGF, FGF2, PDGF-
BB, TGFb1, or VEGFA and imaged at 106magnification with an
inverted microscope. Eight hours later wells were reimaged and
total migration distance was assessed according to gap closure.
Blue: non-transduced; red: non-target; yellow: GIPC1 KD.
(TIF)
Table S1 The set of the top 411 SAM probesets (0% FDR; fold
change $ 2) assessed for clinical relevance to human breast and
ovarian cancers with the globaltest Bioconductor R package.
(DOC)
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